Low expression of iron–sulfur cluster binding protein RFESD predicts adverse clinical outcomes in acute myeloid leukemia

Acute myeloid leukemia (AML) is a devastating hematopoietic malignancy with high heterogeneity and poor outcomes. In this study, we searched for the new biomarker to promote the efficacy of diagnosis, therapy and prognosis of AML by transcriptome and clinical information from the Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) datasets, and Genotype-Tissue Expression (GTEx) projects. RFESD was found to be significantly downregulated in AML, and was confirmed as an independent prognostic factor by univariate Cox regression. A survival prediction nomogram was established with a C-index of 0.762, which indicated reliable prognostic prediction. Function pathway enrichment analysis of differentially expressed genes (DEGs) indicated immune response related pathways in low RFESD expression group. Through gene co-expression and protein‒protein interaction (PPI) network analysis, we identified KLF1 as the hub gene, which was linked to adverse clinical outcomes. Furthermore, we found that low expression of RFESD tended to be positively correlated with immune cells and immune check-points. Finally, drug sensitivity prediction indicated some inhibitors associated with cell-cycle and kinases. Accordingly, our research illustrated that the low expression level of RFESD predicts an adverse prognosis in AML patients.

Authors

Publication Details

Journal
Discover Oncology
Published
2026-11-19
DOI
https://doi.org/10.1007/s12672-026-06319-9
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Low expression of iron–sulfur cluster binding protein RFESD predicts adverse clinical outcomes in acute myeloid leukemia

Jiajia Yuan, Huan Shao, Yin Zhao, Xiaodan Wang
4 links
Discover Oncology
Acute Myeloid Leukemia Research
article

Low expression of iron–sulfur cluster binding protein RFESD predicts adverse clinical outcomes in acute myeloid leukemia

Jiajia Yuan, Huan Shao, Yin Zhao, Xiaodan Wang
article en

Abstract

Acute myeloid leukemia (AML) is a devastating hematopoietic malignancy with high heterogeneity and poor outcomes. In this study, we searched for the new biomarker to promote the efficacy of diagnosis, therapy and prognosis of AML by transcriptome and clinical information from the Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) datasets, and Genotype-Tissue Expression (GTEx) projects. RFESD was found to be significantly downregulated in AML, and was confirmed as an independent prognostic factor by univariate Cox regression. A survival prediction nomogram was established with a C-index of 0.762, which indicated reliable prognostic prediction. Function pathway enrichment analysis of differentially expressed genes (DEGs) indicated immune response related pathways in low RFESD expression group. Through gene co-expression and protein‒protein interaction (PPI) network analysis, we identified KLF1 as the hub gene, which was linked to adverse clinical outcomes. Furthermore, we found that low expression of RFESD tended to be positively correlated with immune cells and immune check-points. Finally, drug sensitivity prediction indicated some inhibitors associated with cell-cycle and kinases. Accordingly, our research illustrated that the low expression level of RFESD predicts an adverse prognosis in AML patients.

Discover Oncology
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon